Oxford, UK-based Glide Technologies has raised £3.2 million to help it progress development of a novel solid dose formulation of osteoporosis drug teriparatide (parathyroid hormone).
The National Institute for Health Research Efficacy and Mechanism Evaluation (EME) Programme is funding a new £1.5 million trial testing a combination of therapies to prevent rapture in patients with brittle bone disease.